MDNA113

MDNA113 is a novel, first-in-class tumor-targeted and tumor-activated bi-functional immunotherapy designed to deliver both an anti-PD1 antibody and an IL-2 Superkine specifically to the tumor microenvironment. It achieves this through high-affinity binding to IL-13Rα2, a tumor-associated antigen overexpressed in many aggressive and immunologically "cold" solid tumors (such as pancreatic, prostate, ovarian, breast, liver, brain cancers). The molecule is engineered with a protease-sensitive linker that masks the IL-2 Superkine domain until it reaches the tumor site—where cancer-specific enzymes (matrix metalloproteases) cleave the linker and activate the drug. This conditional activation minimizes systemic toxicity by reducing peripheral immune stimulation while maximizing local anti-tumor efficacy via simultaneous immune checkpoint blockade (PD1 inhibition) and T cell activation (IL-2 receptor agonism). Preclinical data show durable accumulation in IL-13Rα2-positive tumors with enhanced infiltration of CD8+ T cells and improved tolerability compared to non-masked versions[1][5][7][8].

Other names

BiSKIT